Engineered self-regulating macrophages for targeted anti-inflammatory drug delivery
These findings demonstrate the successful development of engineered macrophages that possess the ability for controlled, autoregulated production of IL-1 based on inflammatory signaling such as via the NF-κB pathway to mitigate the effects of this cytokine for applications in RA or other inflammatory diseases. This system provides proof of concept for applications in other immune cell types as self-regulating delivery systems for therapeutic applications in a range of diseases.
Authors
- Molly Klimak (ORCID: https://orcid.org/0000-0003-4673-9540)
- Kelsey H. Collins (ORCID: https://orcid.org/0000-0001-7348-7348)
- Christine T. N. Pham (ORCID: https://orcid.org/0000-0003-1127-3699)
- Natalia S. Harasymowicz (ORCID: https://orcid.org/0000-0002-2140-4157)
- Kristin L. Lenz
- Luke E. Springer (ORCID: https://orcid.org/0000-0002-0091-1520)
- Farshid Guilak (ORCID: https://orcid.org/0000-0001-7380-0330)
- Amanda Cimino
- Nathan Xu
Institutions
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- University of Utah (US)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1186/s13075-024-03425-3
- Citations
- 10
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.40
Funders
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases